Early QT assessment--how can our confidence in the data be improved?
- PMID: 23278510
- PMCID: PMC3853524
- DOI: 10.1111/bcp.12068
Early QT assessment--how can our confidence in the data be improved?
Abstract
Exposure-response (ER) analysis has emerged as an important tool to interpret QT data from thorough QT (TQT) studies and allows the prediction of effects in the targeted patient population. Recently, ER analysis has also been applied to data from early clinical pharmacology studies, such as single and multiple ascending dose studies, in which high plasma concentrations are often achieved. In line with this, there is an on-going discussion between sponsors, academicians and regulators on whether 'early QT assessment' can provide sufficiently high confidence in assessment of QT prolongation to replace the TQT study. In this article, we discuss how QT assessment can be applied to early clinical studies ('early QT assessment') and what we believe is needed to achieve the same high confidence in the data as we currently obtain from data from the TQT study. The power to exclude a QTc effect exceeding 10 ms in small sample sizes using ER analysis will be discussed and compared with time-matched analysis, as described in the ICH E14 guidance. Two examples of early QT assessment are shared; one negative and one positive, and the challenge in terms of demonstrating assay sensitivity in the absence of a pharmacological positive control will be discussed. Finally, we describe a recent research proposal, which may generate data to support the replacement of the TQT study with data from QT assessment in early phase 1 studies.
Keywords: Early QT assessment; PK/PD thorough QT study; QT; QT/QTc; healthy volunteers.
© 2012 The Authors. British Journal of Clinical Pharmacology © 2012 The British Pharmacological Society.
Figures






Similar articles
-
The IQ-CSRC prospective clinical Phase 1 study: "Can early QT assessment using exposure response analysis replace the thorough QT study?".Ann Noninvasive Electrocardiol. 2014 Jan;19(1):70-81. doi: 10.1111/anec.12128. Epub 2013 Dec 30. Ann Noninvasive Electrocardiol. 2014. PMID: 24372708 Free PMC article. Review.
-
The prospective IQ-CSRC trial: A prototype early clinical proarrhythmia assessment investigation for replacing the ICH E14 thorough QTc (TQT) study.J Pharmacol Toxicol Methods. 2016 Jul-Aug;80:1-8. doi: 10.1016/j.vascn.2016.02.181. Epub 2016 Mar 9. J Pharmacol Toxicol Methods. 2016. PMID: 26903171
-
Establishing assay sensitivity in QT studies: experience with the use of moxifloxacin in an early phase clinical pharmacology study and comparison with its effect in a thorough QT study.Eur J Clin Pharmacol. 2015 Dec;71(12):1451-9. doi: 10.1007/s00228-015-1959-z. Epub 2015 Oct 1. Eur J Clin Pharmacol. 2015. PMID: 26423621 Clinical Trial.
-
The thorough QT/QTc study 4 years after the implementation of the ICH E14 guidance.Br J Pharmacol. 2010 Jan;159(1):49-57. doi: 10.1111/j.1476-5381.2009.00487.x. Epub 2009 Nov 18. Br J Pharmacol. 2010. PMID: 19922536 Free PMC article. Review.
-
ECG Evaluation as Part of the Clinical Pharmacology Strategy in the Development of New Drugs: A Review of Current Practices and Opportunities Based on Five Case Studies.J Clin Pharmacol. 2022 Dec;62(12):1480-1500. doi: 10.1002/jcph.2095. Epub 2022 Jul 1. J Clin Pharmacol. 2022. PMID: 35665514 Free PMC article. Review.
Cited by
-
Can an early phase clinical pharmacology study replace a thorough QT study? Experience with a novel H3-receptor antagonist/inverse agonist.Eur J Clin Pharmacol. 2016 May;72(5):533-43. doi: 10.1007/s00228-016-2023-3. Epub 2016 Feb 16. Eur J Clin Pharmacol. 2016. PMID: 26879827 Clinical Trial.
-
Comparing QT interval variability of semiautomated and high-precision ECG methodologies in seven thorough QT studies-implications for the power of studies intended for definitive evaluation of a drug's QT effect.Ann Noninvasive Electrocardiol. 2017 Jan;22(1):e12416. doi: 10.1111/anec.12416. Epub 2016 Dec 19. Ann Noninvasive Electrocardiol. 2017. PMID: 27995684 Free PMC article.
-
Estimation of QT interval prolongation through model-averaging.J Pharmacokinet Pharmacodyn. 2017 Aug;44(4):335-349. doi: 10.1007/s10928-017-9523-3. Epub 2017 Apr 18. J Pharmacokinet Pharmacodyn. 2017. PMID: 28421417
-
Detection of QTc effects in small studies--implications for replacing the thorough QT study.Ann Noninvasive Electrocardiol. 2015 Jul;20(4):368-77. doi: 10.1111/anec.12227. Epub 2014 Nov 4. Ann Noninvasive Electrocardiol. 2015. PMID: 25367715 Free PMC article.
-
Implications of the IQ-CSRC Prospective Study: Time to Revise ICH E14.Drug Saf. 2015 Sep;38(9):773-80. doi: 10.1007/s40264-015-0325-5. Drug Saf. 2015. PMID: 26162419
References
-
- ICH Harmonized Tripartite Guideline E14. The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. 2005. Available at: http://www.ich.org/cache/compo/276-254-1.html (last accessed 21 December 2012) - PubMed
-
- Shah RR. Drugs, QT interval prolongation and ICH E14: the need to get it right. Drug Saf. 2005;28:115–125. - PubMed
-
- Rodriguez I, Erdman A, Padhi D, Garnett CE, Zhao H, Targum SL, Balakrishnan S, Strnadova C, Viner N, Geiger MJ, Newton-Cheh C, Litwin J, Pugsley MK, Sager PT, Krucoff MW, Finkle JK. Electrocardiographic assessment for therapeutic proteins – scientific discussion. Am Heart J. 2010;160:627–634. - PubMed
-
- Rock EP, Finkle J, Fingert HJ, Booth BP, Garnett CE, Grant S, Justice RL, Kovacs RJ, Kowey PR, Rodriguez I, Sanhai WR, Strnadova C, Targum SL, Tsong Y, Uhl K, Stockbridge N. Assessing proarrhythmic potential of drugs when optimal studies are infeasible. Am Heart J. 2009;157:827–836. 836. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources